fda approves first oral glp-1 obesity drug august 1 2025 pill for from Wegovy maker Novo Nordisk FDA approves Foundayo, an oral

RR, risk ratio

In the larger SELECT trial in 2023, patients with heart failure, atherosclerotic disease, and overweight or obesity, treated with semaglutide 2.4 mg showed reduction in major adverse cardiac events (MACE) and heart failure end points regardless of heart failure subgroup being HFrEF or HFpEF [56,57,58]

HIV Articles Back Risk of Gastrointestinal Adverse Events Associated With Glucagon-Like Peptide-1 Receptor Agonists for Weight Loss JAMA

Although the most commonly reported adverse events were gastrointestinal side effects such as nausea, vomiting, and diarrhoea, the treatment was well tolerated in the study population [59, 60]

With inspiration from Rolf Mentlein in Kiel, Holst and Deacon showed that the GLP-1 molecule was cleaved by the enzyme dipeptidyl-peptidase-4(DPP-4) in vivo and that inhibitors of this enzyme could completely protect the molecule (43)

Skelley JW, Swearengin K, York AL, Glover LH